← Leaderboards
Joel Reid
Mayo Clinic Rochester
$1,043,778
Attributed
$1,043,778
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $349.8K · FY2013–23$500K$375K$250K$125K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$1,043,778 · 3
By mechanism
N02$556,907 · 1
N01$486,871 · 2
Top collaborators
No co-investigators on record.
Most similar at Mayo Clinic Rochester
Same institution · by research overlap
- Evanthia Galanis$13,573,895
- Kah-Whye Peng$11,311,466
- Scott H Kaufmann$29,002,745
- Harmeet Malhi$6,274,066
- Erin Frazee Barreto$1,086,246
Others in their field
Top investigators on “Drug Kinetics”
- Leonard Freedman · Leidos Biomedical Research, Inc.$241,865,009
- Sharon A Nachman · Johns Hopkins University$194,646,762
- Carol Nesel · Westat$147,274,423
- Barbara Driver · Westat, Inc.$103,746,400
- Ronald T Mitsuyasu · University Of California Los Angeles$99,239,507
- Lynn Briscoe · Leidos Biomedical Research, Inc.$93,714,869
Research focus
Drug KineticsPlasmaBiological AvailabilitySmall MoleculeBaseRouteScheduleAnti-CancerTumorSamplingPre-ClinicalPerformanceContractsCancer PatientPharmacologyPreclinical EfficacyContractorInvestigationProceduresDesignBiologicalPharmacodynamicsAnalytical MethodClinical Trials
Grant awards (13)
Pharmacokinetic Studies with Selected Anticancer Compounds in NSG Mice$43,674
N02 · FY2023 · CA · contact PI
Pharmacokinetic Studies with Selected Anticancer Compounds in NSG Mice$43,674
N02 · FY2022 · CA · contact PI
Contract Orientation & Kick Off Meeting in support of IDIQ "Preclinical Pharmacokinetic and Pharmacology Evaluations of Agents Being Developed for Cancer Patients." R&D Services$3,000
N01 · FY2021 · CA · contact PI
Pharmacokinetic Studies with Selected Anticancer Compounds in NSG Mice$65,511
N02 · FY2020 · CA · contact PI
NExT NX232-107-158-006 TO#3 Milestone 3 (base) - PK & Bioavail Stud w/Selected Anticancer Compounds in Mice, PK & Pharm Evals of Agents Being Developed for Cancer Patients, HHSN261201600024I/HHSN26100$117,005
N02 · FY2019 · CA · contact PI
Title: Pharmacokinetic and Bioavailability Studies and Analytical Support with Selected Anticancer Compounds in Mice.Period of Performance: 6/27/17 - 4/27/2022$68,105
N02 · FY2018 · CA · contact PI
NExT NX232-107-158-006 TO#3 Milestone 3 (base) - PK & Bioavail Stud w/Selected Anticancer Compounds in Mice, PK & Pharm Evals of Agents Being Developed for Cancer Patients, HHSN261201600024I/HHSN26100$33,430
N02 · FY2018 · CA · contact PI
Title: Pharmacokinetic and Bioavailability Studies and Analytical Support with Selected Anticancer Compounds in Mice.Period of Performance: 6/27/17 - 4/27/2022$167,190
N02 · FY2017 · CA · contact PI
NExT NX232-107-158-006 TO#3 Milestone 3 (base) - PK & Bioavail Stud w/Selected Anticancer Compounds in Mice, PK & Pharm Evals of Agents Being Developed for Cancer Patients, HHSN261201600024I/HHSN26100$16,715
N02 · FY2017 · CA · contact PI
Preclinical Pharmacokinetic and Pharmacological Studies of Antitumor and other Th$348,203
N01 · FY2016 · CA · contact PI
IGF::OT::IGF KICK OFF MEETING, PRECLINICAL PHARMACOKINETIC & PHARMACOLOGICAL EVALUATIONS OF AGENTS BEING DEVELOPED FOR CANCER PATIENTS, 7/1/2016-9/30/16, HHSN261201600024I$1,603
N02 · FY2016 · CA · contact PI
Preclinical Pharmacokinetic and Pharmacological Studies of Antitumor and other Th$76,567
N01 · FY2015 · CA · contact PI
Preclinical Pharmacokinetic and Pharmacological Studies of Antitumor and other Th$59,101
N01 · FY2013 · CA · contact PI